EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MindBio Therapeutics's enterprise value is C$11.74 Mil.
MindBio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-3.04 Mil. Therefore, MindBio Therapeutics's EV-to-EBITDA for today is -3.86.
The historical rank and industry rank for MindBio Therapeutics's EV-to-EBITDA or its related term are showing as below:
XCNQ:MBIO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.49 Med: -3.83 Max: -2.3
Current: -3.86
During the past 3 years, the highest EV-to-EBITDA of MindBio Therapeutics was -2.30. The lowest was -4.49. And the median was -3.83.
XCNQ:MBIO's EV-to-EBITDA is ranked worse than 100% of 465
companies
in the Biotechnology industry
Industry Median: 9.34
vs XCNQ:MBIO: -3.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
MindBio Therapeutics EV-to-EBITDA Historical Data
The historical data trend for MindBio Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MindBio Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, MindBio Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindBio Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MindBio Therapeutics's EV-to-EBITDA falls into.
MindBio Therapeutics's current Enterprise Value is C$11.74 Mil.
MindBio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
MindBio Therapeutics's PE Ratio for today is calculated as:
MindBio Therapeutics's share price for today is C$0.055.
MindBio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.026.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of MindBio Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
MindBio Therapeutics (XCNQ:MBIO) Business Description
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:MBIO has been successfully added to your 